Investors too optimistic, should sell the coronavirus vaccine news – Bank of America
|Investors have become too optimistic over prospects of swift global economic recovery on potential coronavirus vaccines and should be selling the news of positive results of experimental vaccines, Bank of America’s top strategist said in light of the firm’s most recent fund manager survey, according to CNBC.
According to the bank's latest fund manager survey, investor bullishness has surged to its highest point since January 2018, and fund managers' allocations to stocks have neared the 50% threshold that indicates "extremely bullish" levels.
Two drugmakers, Pfizer and Moderna, announced positive results of their experimental vaccines earlier this month, triggering hopes for faster economic recovery and rotation of money from defensive assets to small caps, emerging market assets and energy.
"Reopening rotation can continue in the fourth quarter but we say 'sell the vaccine' in coming weeks and months as we think we're close to 'full bull,'" the team led by Michael Hartnett wrote in the Tuesday note, according to Business Insider.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.